CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
Historically, metastatic melanoma was considered a highly lethal disease. However, recent advances in drug development have allowed a significative improvement in prognosis. In particular, BRAF/MEK inhibitors and anti-PD1 antibodies have completely revolutionized the management of this disease. None...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/6/1334 |
| _version_ | 1797532322446180352 |
|---|---|
| author | Mattia Garutti Giada Targato Silvia Buriolla Lorenza Palmero Alessandro Marco Minisini Fabio Puglisi |
| author_facet | Mattia Garutti Giada Targato Silvia Buriolla Lorenza Palmero Alessandro Marco Minisini Fabio Puglisi |
| author_sort | Mattia Garutti |
| collection | DOAJ |
| description | Historically, metastatic melanoma was considered a highly lethal disease. However, recent advances in drug development have allowed a significative improvement in prognosis. In particular, BRAF/MEK inhibitors and anti-PD1 antibodies have completely revolutionized the management of this disease. Nonetheless, not all patients derive a benefit or a durable benefit from these therapies. To overtake this challenges, new clinically active compounds are being tested in the context of clinical trials. CDK4/6 inhibitors are drugs already available in clinical practice and preliminary evidence showed a promising activity also in melanoma. Herein we review the available literature to depict a comprehensive landscape about CDK4/6 inhibitors in melanoma. We present the molecular and genetic background that might justify the usage of these drugs, the preclinical evidence, the clinical available data, and the most promising ongoing clinical trials. |
| first_indexed | 2024-03-10T10:57:29Z |
| format | Article |
| id | doaj.art-5e613c046ba346f4a39bb9c7c4036f03 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T10:57:29Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-5e613c046ba346f4a39bb9c7c4036f032023-11-21T21:46:14ZengMDPI AGCells2073-44092021-05-01106133410.3390/cells10061334CDK4/6 Inhibitors in Melanoma: A Comprehensive ReviewMattia Garutti0Giada Targato1Silvia Buriolla2Lorenza Palmero3Alessandro Marco Minisini4Fabio Puglisi5CRO Aviano National Cancer Institute IRCCS, 33081 Aviano, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyCRO Aviano National Cancer Institute IRCCS, 33081 Aviano, ItalyDepartment of Medicine (DAME), University of Udine, 33100 Udine, ItalyCRO Aviano National Cancer Institute IRCCS, 33081 Aviano, ItalyHistorically, metastatic melanoma was considered a highly lethal disease. However, recent advances in drug development have allowed a significative improvement in prognosis. In particular, BRAF/MEK inhibitors and anti-PD1 antibodies have completely revolutionized the management of this disease. Nonetheless, not all patients derive a benefit or a durable benefit from these therapies. To overtake this challenges, new clinically active compounds are being tested in the context of clinical trials. CDK4/6 inhibitors are drugs already available in clinical practice and preliminary evidence showed a promising activity also in melanoma. Herein we review the available literature to depict a comprehensive landscape about CDK4/6 inhibitors in melanoma. We present the molecular and genetic background that might justify the usage of these drugs, the preclinical evidence, the clinical available data, and the most promising ongoing clinical trials.https://www.mdpi.com/2073-4409/10/6/1334CDK4/6CDK4CDK6melanomaPalbociclibRibociclib |
| spellingShingle | Mattia Garutti Giada Targato Silvia Buriolla Lorenza Palmero Alessandro Marco Minisini Fabio Puglisi CDK4/6 Inhibitors in Melanoma: A Comprehensive Review Cells CDK4/6 CDK4 CDK6 melanoma Palbociclib Ribociclib |
| title | CDK4/6 Inhibitors in Melanoma: A Comprehensive Review |
| title_full | CDK4/6 Inhibitors in Melanoma: A Comprehensive Review |
| title_fullStr | CDK4/6 Inhibitors in Melanoma: A Comprehensive Review |
| title_full_unstemmed | CDK4/6 Inhibitors in Melanoma: A Comprehensive Review |
| title_short | CDK4/6 Inhibitors in Melanoma: A Comprehensive Review |
| title_sort | cdk4 6 inhibitors in melanoma a comprehensive review |
| topic | CDK4/6 CDK4 CDK6 melanoma Palbociclib Ribociclib |
| url | https://www.mdpi.com/2073-4409/10/6/1334 |
| work_keys_str_mv | AT mattiagarutti cdk46inhibitorsinmelanomaacomprehensivereview AT giadatargato cdk46inhibitorsinmelanomaacomprehensivereview AT silviaburiolla cdk46inhibitorsinmelanomaacomprehensivereview AT lorenzapalmero cdk46inhibitorsinmelanomaacomprehensivereview AT alessandromarcominisini cdk46inhibitorsinmelanomaacomprehensivereview AT fabiopuglisi cdk46inhibitorsinmelanomaacomprehensivereview |